SeaSpine Expands Ventura™ NanoMetalene® Implant Offering to Accommodate Larger Range of Posterior Procedures
Carlsbad, Calif. / Jan. 31, 2018 – SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the portfolio expansion of the Ventura™ NanoMetalene® posterior interbody device. Ventura NanoMetalene, which has been commercially available since 2015, has expanded its size offerings to accommodate a larger range of posterior procedures and a wider variety of patient anatomies. These new sizes include additional lengths and oblique placement options with sagittally oriented lordosis.
The Ventura interbody devices feature proprietary NanoMetalene surface technology. NanoMetalene describes a sub-micron layer of commercially pure titanium molecularly bonded to a PEEK implant using a high-energy, low-temperature process referred to as atomic fusion deposition. It is designed to provide implants a bone-friendly titanium surface on endplates and throughout graft apertures, while retaining the benefits associated with traditional PEEK implants, such as biocompatibility, a modulus of elasticity similar to bone, and excellent radiographic visibility for post-operative imaging.
Ali Chahlavi, MD, a neurosurgeon practicing in Jacksonville, FL and an early adopter of NanoMetalene, commented, “NanoMetalene has been an integral part of my fusion procedures. These implants deliver the same surface characteristics of titanium while maintaining PEEK’s radiolucency for clear assessment of fusion post-operatively, which has not always been my experience with a full titanium device.” With respect to the new lordotic options, he said, “the additional lordosis will improve my ability to restore better natural alignment to my patients.”
SeaSpine’s entire portfolio of posterior lumbar NanoMetalene interbody devices is cleared for use with both autograft and allograft. Having the additional indication allows surgeons more bone grafting options, including using Ventura NanoMetalene with SeaSpine’s new line of allograft demineralized bone fiber products.
“NanoMetalene is a differentiated product in a market that has become increasingly competitive,” stated Troy Woolley, Vice President of Marketing. “The expansion of this technology coupled with our advanced orthobiologics demonstrates our commitment to provide complementary, cost-effective procedural solutions to surgeons, hospitals and patients.”
About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
Forward-Looking Statements
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements may include, but are not limited to, statements relating to: the design and other benefits of the Ventura NanoMetalene portfolio; its ability to restore better natural alignment to patients; and the ability of the Ventura NanoMetalene product to provide complementary, cost-effective procedural solutions to surgeons, hospitals and patients. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the ability of the expanded Ventura NanoMetalene portfolio to perform as designed and intended and to meet the clinical needs of surgeons and patients; the limited clinical experience supporting the commercial launch of new products and the risk that such products may require substantial additional development activities, which could introduce unexpected expense and delay; the lack of long-term clinical data supporting the safety and efficacy of the Company’s products; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.
###
Investor Relations Contact
Lynn Pieper
(415) 937-5402
ir@seaspine.com
